P822 Factors associated with oncogenic human papillomavirus prevalence among australian women following vaccine introduction

Background In Australia, high and widespread uptake of the quadrivalent human papillomavirus (HPV) vaccine has led to substantial population-level reductions in the prevalence of HPV16/18 in women aged ≤35 years. We assessed risk factors for oncogenic HPV detection among 18–35 year old women in 2015–2018. Methods Women attending health services across Australia provided a self-collected (vaginal) or clinician-collected (cervical) specimen for HPV genotyping (Roche Linear Array) and completed a questionnaire. HPV vaccination status was validated against the National HPV Vaccination Program Register. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated for factors associated with detection of any oncogenic HPV (HPV16/18/31/33/35/39/45/51/52/56/58/59/66/68). Results Among 1,643 women, vaccine coverage (≥one dose) was 61.5% (69.1%, 58.7% and 41.1% among those 18–24, 25–29 and 30+ years, respectively). Oncogenic HPV prevalence was 25.4% (95% CI: 23.2–27.6%). In univariable analysis, risk factors for detection included younger age (p-trend Conclusion Oncogenic HPV was commonly detected among young Australian women; prevalence was influenced by risk factors related to sexual behaviour. In contrast, prevalence of quadrivalent vaccine-targeted types 16/18 was very low and influenced only by vaccination status. Vaccination has changed the epidemiology of HPV infection in Australia. Disclosure No significant relationships.